Strides Pharma clears USFDA inspection of Alathur facility

Strides Pharma said in a filing, the company's formulations unit in Alathur was inspected by the US Food and Drug Administration (USFDA) in August 2019 and has received the establishment inspection report (EIR), confirming successful closure of the inspection.

New Delhi: Strides Pharma Science on Wednesday said the inspection by the US health regulator of its formulations facility in Alathur in Kerala has been completed without any adverse observations.

In a regulatory filing, the company said the company's formulations unit in Alathur was inspected by the US Food and Drug Administration (USFDA) in August 2019.

It has received the establishment inspection report (EIR), thereby confirming the successful closure of the inspections, the company added.

"The inspection conducted in August 2019 had concluded with zero 483 observations," Strides Pharma Science said.

Read Also: Strides Pharma gets USFDA nod for generic version of Vesicare Tablets to treat overactive bladder

Under form 483 USFDA issues observations to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related acts.

The regulator notifies the company's management of objectionable conditions.

Strides further said, "The facility has recently completed a significant capacity expansion and will support the growth momentum for the US business."

Read Also: Strides Pharma re-enters injectable biz by infusing Rs 280 crore for controlling stake in Stelis Biopharma